A.M. Ghelfi , G. Miranda , L.S. Voto , J.M. Zilberman , M.A. Del Sueldo , F. Waisman , M. Baroni , M.V. Ferretti , J.P. Moran , A. Corrales-Barboza , R. Mondino , M.P. Pérez , P.G. Irusta , L. Meccia , E. Martínez Marissi , M.L. Baiche , A.M. Delucchi , P.D. Rodríguez , N.F. Renna
{"title":"Statins and preeclampsia: An update from the Working Group on Hypertension in Women, Argentine Society of Hypertension","authors":"A.M. Ghelfi , G. Miranda , L.S. Voto , J.M. Zilberman , M.A. Del Sueldo , F. Waisman , M. Baroni , M.V. Ferretti , J.P. Moran , A. Corrales-Barboza , R. Mondino , M.P. Pérez , P.G. Irusta , L. Meccia , E. Martínez Marissi , M.L. Baiche , A.M. Delucchi , P.D. Rodríguez , N.F. Renna","doi":"10.1016/j.hipert.2025.03.001","DOIUrl":null,"url":null,"abstract":"<div><div>Hypertensive disorders of pregnancy (HDP) affect 5–10% of pregnancies. Preeclampsia (PE) is a severe complication of HDP, associated with high maternal, fetal, and neonatal morbidity and mortality. The pathophysiology of PE involves endothelial dysfunction, vasoconstriction, and impaired placental perfusion, leading to systemic inflammation and multi-organ dysfunction. It has been suggested that statins, traditionally contraindicated during pregnancy, could play a role in this context. Some studies propose that pravastatin, a hydrophilic statin, may not have the same teratogenic effects as lipophilic statins, potentially improving maternal vascular status and significantly reducing the risk of PE. Considering this, the Working Group on Hypertension in Women of the Argentine Society of Hypertension undertook a review of the topic and its current implications.</div></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"42 3","pages":"Pages 147-155"},"PeriodicalIF":1.3000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hipertension y Riesgo Vascular","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1889183725000297","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Hypertensive disorders of pregnancy (HDP) affect 5–10% of pregnancies. Preeclampsia (PE) is a severe complication of HDP, associated with high maternal, fetal, and neonatal morbidity and mortality. The pathophysiology of PE involves endothelial dysfunction, vasoconstriction, and impaired placental perfusion, leading to systemic inflammation and multi-organ dysfunction. It has been suggested that statins, traditionally contraindicated during pregnancy, could play a role in this context. Some studies propose that pravastatin, a hydrophilic statin, may not have the same teratogenic effects as lipophilic statins, potentially improving maternal vascular status and significantly reducing the risk of PE. Considering this, the Working Group on Hypertension in Women of the Argentine Society of Hypertension undertook a review of the topic and its current implications.
期刊介绍:
La mejor publicación para mantenerse al día en los avances de la lucha contra esta patología. Incluye artículos de Investigación, Originales, Revisiones, Casos clínicos, Aplicación práctica y Resúmenes comentados a la bibliografía internacional. Además, es la Publicación Oficial de la Sociedad española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial.